Overview

Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study

Status:
Terminated
Trial end date:
2018-09-04
Target enrollment:
Participant gender:
Summary
Treatment of refractory hemochromatosis rheumatism by Anakinra. Prospective, multicenter, non-randomised, single-arm, open-label, phase II trial.
Phase:
Phase 2
Details
Lead Sponsor:
Rennes University Hospital
Treatments:
Interleukin 1 Receptor Antagonist Protein